Exelixis | EXEL - Assets


Exelixis reported $2.49B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bayer EUR 107.29B 659M Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.49B 99.36M Jun/2026
Genmab DKK 12.52B 139M Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.27T 391.77B Sep/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026